GSK allots as much as $2B for "bolt-on acquisitions" in India

10/3/2011 | Wall Street Journal, The

GlaxoSmithKline is looking to spend between $500 million and $2 billion on smaller, "bolt-on acquisitions" in India to secure its position in emerging markets, CEO Andrew Witty said. He said GSK is not willing to overpay. "We already have an enviable brand in India so there is no need for us to pay a strategic premium," Witty said. "Others might need to do that, but we don't."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Executive Medical Director
Aspirus Network Inc
Wausau, WI
Medical Director - Cataract
Abbott
Santa Ana, CA
Director, Membership
The Food and Drug Law Institute
Washington, DC
Manager, Compliance
Stryker
Fremont, CA